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ABSTRACT 
Mass spectrometry imaging (MSI) can uniquely detect thousands of compounds allowing both 
their identification and localization within biological tissue samples. MSI is an interdisciplinary 
science that crosses the borders of physics, chemistry and biology, and enables local molecular 
analysis at a broad range of length scales: From the subcellular level to whole body tissue 
sections. The spatial resolution of some mass spectrometers now allows nano-scale research, 
crucial for studies in nanomedicine. Recent developments in MSI have enabled the optimization 
and localization of drug delivery with nanoparticles within the body and in specific organs such 
as kidney, liver and brain. Combining MSI with nanomedicine has vast potential, specifically in 
the treatment of neurological disorders, where effective drug delivery has been hampered by the 
blood-brain barrier. This review provides an introduction to MSI and its different technologies, 
with the application of MSI to nanomedicine and the different possibilities that MSI offers to 
study molecular signals in the brain. Finally, we provide an outlook for the future and exciting 
potential of MSI in nanoparticle-related research. 
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INTRODUCTION 
As the control center of the body, the brain regulates other organs and systems as well as gives 
rise to movement, thoughts, feelings, and memory. Concomitant with an increase in life 
expectancy, the brain has been subjected to a prolonged aging process and an increased risk for 
the development of neurodegenerative disorders such as Alzheimer’s, Parkinson’s and dementia. 
To date, there are no effective therapies for such diseases, especially due to the restricted passing 
of any potential treatment across the blood-brain barrier (BBB). The BBB, a semipermeable 
membrane formed by endothelial tight junctions, separates the blood vessels and the central 
nervous system (CNS). The BBB protects the brain by restricting passage of pathogens, toxins or 
hormones circulating in the blood. Unfortunately, this filter is too efficient and prohibits many 
active therapeutic molecules to reach the brain, complicating the treatment of many neurological 
diseases. Drug transit across the BBB is essential to treat some diseases such as cancer, 
Parkinson´s disease, Alzheimer´s disease and other neurological disorders. In recent years, 
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nanoparticles have emerged as the method with greatest potential for effective drug delivery due 
to their ability to maintain drug levels in the therapeutic range as well as to increase the half-life, 
solubility, stability and permeability of drugs across the BBB.1 Thus, the detection and 
monitoring of nanoparticles as drug carriers are critical in drug discovery and development.  
Mass spectrometry imaging (MSI) has demonstrated vast potential in clinical research and drug 
discovery, including its early application in the detection of nanoparticles.  Mass spectrometry 
(MS) is a unique interdisciplinary technique combining physics, chemistry and biology to analyze 
the molecular composition of any sample. This technique allows us to understand biological 
processes from a sub- to multicellular level and from cells to whole biological systems. Initially, 
MS was predominantly used within the field of physics. A mass spectrometer measures the mass-
to-charge ratios (m/z) of ions and can determine the molecule’s mass if the charge is known. A 
mass spectrometer consists of three different parts: an ion source, which ionizes the analytes; 
mass analyzers, which separate the analytes based on their molecular weight and a detector that 
registers the presence of different analytes. With the development of soft ionization techniques in 
the 1980’s, such as matrix-assisted laser desorption/ionization (MALDI)2, 3 and electrospray 
ionization (ESI),4 MS became more suitable for biological studies. Over the last three decades, 
MS has become an important analytical technique in biological and medical applications.  
Based in MS, mass spectrometry imaging (MSI) developed as a relatively new technique to 
visualize and study the spatial distribution of biomolecules such as proteins, peptides, lipids, 
drugs and metabolites in biological tissue sections. Label-free imaging with mass spectrometry 
uses an intrinsic molecular parameter, the molecular mass, to visualize the distribution of a wide 
variety of biomolecules from sample surfaces. This is achieved by manipulating the ions in 
electric/magnetic fields or by measuring their time-of-flight (TOF). To use a mass spectrometer 
as an imaging instrument, the spectrometer needs to be equipped with a desorption and ionization 
source that can generate local information, an automated sample or beam manipulation system, 
automatic data acquisition and registration system and visualization software. The detected signal 
is proportional to the amount of the compound present in the sample. Each mass spectrum 
reflects the local molecular composition at a given pair of x and y coordinates. All locally 
acquired mass spectra from the tissue constitute an image dataset analogous to pixels in a digital 
photograph. Images show the distribution of the selected compound within the tissue section 
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according to the intensity distribution of a specific m/z value that is extracted from all the 
collected spectra. The relative abundance of that ion in each pixel can be visualized by a color 
intensity scale in a two-dimensional (2D) map. Images are generated by extracting data for the 
corresponding m/z ranges from the spatially acquired MS data files.  
MSI provides ex-vivo molecular information that complements  in-vivo and in-vitro 
imaging techniques, used for NP detection, such as magnetic resonance imaging (MRI),5 positron 
emission tomography (PET),6 autoradiography7 or fluorescence imaging8, 9 MSI does not require 
labelled molecules and can reach high spatial resolution (as low as 1 µm), two important 
advantages over other techniques. Furthermore, in a single experiment, thousands of molecules 
(targeted or untargeted) can be detected at the same time. Thus, MSI is suitable to study 
biodistributions in both large samples (rat or mouse whole-body tissue sections) and small tissue 
organs, such as the brain,10 the kidney11 or the eyes12 with a relatively high spatial resolution. 
Subsequent developments that allowed instrument control as well as improved data acquisition 
and processing enabled imaging of endogenous compound distributions within thin tissue 
sections (Figure 1).   
In the last decade, due to rapid instrumentation and sample preparation advances, the MSI 
approach expanded its range of applications in the pharmaceutical,13 biomedical14 and clinical 
fields.15, 16 MSI is used in cancer research,17, 18 ophthalmology,12 degenerative diseases such as 
osteoarthritis19 and neurology20 but it is not limited to specific therapeutic areas. MSI 
instrumentation, methods and protocols have been developed to study the spatial distribution of 
endogenous compounds (such as lipids, peptides, and proteins) as well as exogenous compounds 
(such as polymers or pharmaceutical compounds) on complex surfaces. The imaging of 
pharmaceuticals and their metabolites is an essential source of information in drug discovery and 
development.13 Here, we review different MSI innovations and how they are deployed in 
combination with newly developed nanoparticles based drug delivery systems in tissues and brain 
cells. MSI can follow and quantify the uptake of these nanoparticle carriers, the released drugs 
and their metabolites.  
STATE OF THE ART IN MSI 
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Several reviews21-23 have extensively covered various aspects of MSI technology and application.  
Below, we focus on three ionization techniques with the greatest potential to be used in 
nanomedicine: SIMS, MALDI and DESI (Figure 2). 
Secondary ion mass spectrometry (SIMS) is the oldest MSI technique.24, 25 
Traditionally, SIMS has been applied in the domain of surface and solid-state physics. In SIMS, 
the sample surface is bombarded with primary ion particles, generating secondary ions that are 
analyzed. The primary ions, usually elemental ions generated from a liquid metal ion gun 
(LMIG), lose their energy (typically in 10–30 keV range)  in electronic and nuclear collisions 
inside the target material.26 Part of the energy is then transferred to other atoms and molecules, 
causing the secondary ions to be released from the sample surface. The particles are sputtered 
within 5–10 nm from the primary ion indent at high spatial resolution (as low as 50 nm). In the 
low-current static SIMS measurement, only one ion hits the local environment. Only a small 
fraction of atoms and molecules are ionized in the sputtering process, typically less than 1% of 
the total sputtered material, and form the basis of SIMS analysis.27  
Over the several last years and with enhanced modifications, SIMS has been deployed in 
biomedical applications,28 imaging cells29 and tissue sections.30 With different sample surface 
modifications, SIMS can analyze abundant lipids and small peptides.31, 32 For matrix-enhanced 
(ME)-SIMS, the uppermost layer of the surface is covered with a matrix (ME-SIMS)33, 34 in metal 
assisted (MetA)-SIMS, the top layer is sputter-coated with a thin layer of metal.35-37 In both 
cases, the sputtering efficiency and the secondary molecular ion yield increases. Another 
advancement in SIMS technology was the replacement of the traditional LMIG sources by cluster 
ion sources (Aun
+, Bin
+, SF5 
+,C60
+, ...), which increased signal intensity, quality of the image and 
provided novel depth profiling capabilities.38-41  
Recently, the energy range of primary ions used in SIMS has been moved from keV into 
the MeV domain, which has completely different desorption mechanisms. In contrast to low 
energy ions in the keV region, the MeV ion beams have the ability to desorb larger molecular 
fragments, with relatively high probabilities to desorb unfragmented molecular ions. This 
desorption mechanism occurs due to the electronic excitation of surface molecules when using 
high energy ions.42, 43 Although this new development shows great promise the use of MeV 
energy ions is limited to accelerator facilities and focusing of the energetic primary ion beam is 
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challenging.  As a result, its use is limited to carefully selected biological problems.44, 45 One of 
the major limitations of SIMS is its low sensitivity to larger molecules and very high ion 
suppression, which prevents separating and identifying small isobaric compounds. The latter 
limitation has been overcome with some new advances, such as a parallel tandem MS (MS/MS) 
system on the TRIFT II nano-TOF46 and fusion with the Thermo Orbitrap.  
Matrix-assisted laser desorption/ionization (MALDI) is the most commonly used MSI 
technique with the widest applications in different biomedical fields, due to its high sensitivity, 
speed, broad molecular mass range (approx. 30 000 Da on tissue sections) and spatial resolution. 
The use of MALDI for the imaging of biological tissue samples is often performed in situ with 
thin tissue sections (8–16 µm). Samples for analysis are often subjected to different sample 
preparation strategies to improve the detection of the molecular species in question.47 In MALDI, 
an analyte is co-crystallized with a matrix in a molar ratio of 10-2–10-6. The sample is then laser 
irradiated with nanoseconds of UV-laser impulsions, whose energy is absorbed by the matrix 
molecules. Ions are produced by an excess of protons above the surface due to the fragmentation 
of the acidic matrix molecules.  
Commonly, MALDI is used with one of two different laser types, the N2 (337 nm) or 
neodymium-doped yttrium aluminum garnet (Nd:YAG; 355 nm) lasers, with repetition rates of 
200–1000 Hz and typical pulse lengths of ≤3 ns. Over time, the laser spot size was reduced from 
100–150 to 20 µm48 and then 1 µm, allowing the direct imaging of single cells and tissues at 
subcellular spatial resolution using a transmission geometry configuration.49 In addition to spatial 
resolution, breakthroughs in acquisition speed have recently been made. For example, the 
rapifleX MALDI TissuetyperTM (Bruker) enables acquisition rates up to 50 pixels/s with a 10-
kHz laser and two scanning mirrors that allow the laser beam to be rapidly moved across the 
sample.50 Several studies have demonstrated the potential of MALDI for imaging specific 
peptides and protein compounds; these include the distribution of neuropeptides,51, 52 tumor 
delineation in the pituitary gland,53 molecular phenotyping of CNS glial cells54 and endogenous 
peptide markers for Usher’s55 and Parkinson’s diseases.56  
Desorption electrospray ionization (DESI) imaging is a relatively new MSI technique, 
emerging from the laboratory of Cooks et al. in 2004.57 DESI combines the advantages of 
electrospray ionization (ESI) and other desorption ionization techniques such as SIMS and laser 
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desorption, without the need for matrix application, making it fast and easily automatable. Solid 
samples produce gaseous, multiply charged ions in the form of [M+nH]n+ or [M-nH]n-, a 
characteristic feature of the ESI method. To perform DESI imaging, the sample is placed onto a 
target which can be a glass slide, an ITO slide or directly in situ. The surface to be analyzed is 
mounted on a movable stage in aid of proper sample positioning. Solvent is electrosprayed under 
gas-assisted supersonic conditions onto the sample through a nozzle, which produce desorbed 
ions at ambient temperature. The most common DESI probe design allowed a lateral resolution of 
better than 400 µm on rat brain tissue58 but with a use of “edge sampling” the lateral resolution 
was improved to 40 µm.59 DESI has many advantages that enable its application in many 
different areas. First, it does not require matrix application, which allows faster sample 
preparation and facilitates detection of low mass species. Second, biomolecules are ionized at 
ambient temperature, enabling the study of tissue surfaces in a non-destructive manner.57 Third, 
DESI can be combined with different mass spectrometers and mass analyzers.57, 60 DESI has been 
combined with an ion-mobility TOF mass spectrometer to probe the conformations of proteins 
desorbed from an insulating surface59 and also linked with a linear trap quadrupole (LTQ)-based 
mass spectrometer (Figure 3). DESI has been deployed for the rapid profiling of bacteria without 
any sample preparation,61 the detection of explosives62, 63 and plant tissue profiling for alkaloid 
distribution (first MSI experiment).57 DESI has been used also to study brain lipids,64, 65 natural 
products in algae66 and antifungal molecules in seaweed.67 The detection of drugs in the brain is 
also possible using DESI68 with the potential to detect drugs, drug metabolites and endogenous 
compounds in the same experiment. Other applications in the biomedical field as well as in 
pharmaceutical/industrial and forensics sciences will likely be explored.69  
 Reactive DESI. An important modification was made to DESI, termed reactive DESI, in 
2009.70 Reactive DESI sprays reagent solutions, that react very quickly with the targeted 
molecular entity, contrary to the conventional solvent spray. In one study, betaine aldehyde was 
incorporated in the spray solvent to react with the alcohol group of cholesterol by nucleophilic 
addition forming a hemiacetal salt. Using this set-up, the spatial distribution of cholesterol was 
quantitatively determined in human serum and rat brain tissues, respectively.70 Reactive DESI is 
very useful for studying the spatial distribution of lipids and their profiles, successfully increasing 
the signal-to-noise ratio of low mass lipids in the range of m/z 250–350 and of 
phosphoethanolamines in rat brain and zebrafish tissues.71 Reactive DESI can also distinguish 
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healthy from injured rat spinal cord by detecting eicosanoid compounds from lipid peroxidation 
in the injured samples. Dinitrophenylhydrazine (DNPH) at 100 ppm has been added to the 
solvent for the reactive DESI experiments, and the images were obtained in negative and positive 
ion modes.72 Unfortunately, quantification from these images was not possible due to the 
differences in ionization efficiency. As one of the newer MSI techniques, reactive DESI will 
benefit from further development and optimization. 
Complementary approaches. As noted, all three techniques have certain limitations, which can 
be overcome by their complementary characteristics. It is imperative to select the method that 
best meets the research question posed.73 Regardless of the selected method, sample integrity 
must be maintained for proper analysis. Appropriate sample preparation is thus paramount, which 
is reviewed in detail elsewhere.21, 23 MSI can be complemented with in vivo molecular techniques 
such as MRI. Combined, MSI and MRI have been used to study drug delivery in a rat brain 
perfusion model74 as well as the spatial distribution of alkaloids in plants and fruits.75 MSI and 
MRI can be used to study the whole body76 as well as individual organs. For example, co-
registration of the data obtained from MALDI with that from MRI and immunohistochemistry 
(hematoxylin and eosin staining) using PAXgene fixation provided 3D information about the 
kidney post-infection, an approach that could be applied to other clinically relevant questions.77, 
78  
MONITORING DRUG DELIVERY AND METABOLISM IN THE BRAIN USING MSI 
MSI has been applied for the study of neurodegenerative diseases and biomarker studies over the 
last decade, including research on the distribution of Aβ peptides that co-localize with different 
elements,79, 80 neuropeptides in Parkinson’s disease56 and global changes in phospholipid 
distributions in the 5xFAD transgenic mouse model for Alzheimer’s disease.81 MSI offers the 
unique capability of simultaneously detecting the hallmark morphological changes as well as 
related biomarkers of neurodegeneration, making it a powerful monitoring tool for the 
pathogenesis and classification of these diseases. MSI also has been successfully used for 
imaging drug distribution in different organs,  such as clozapine and its metabolites in the brain, 
lung and kidney by DESI,68 the NHBA neuroprotective drug in a whole body mouse tissue 
section by DESI82 and crystal-like structures in rabbit kidney by complementary DESI and 
SIMS.83 Using MSI, it was possible to determine if a drug penetrated the BBB by correlating the 
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location of the drug with the heme of blood cells (Figure 3).84 Once the drug reaches the brain, 
MSI can also determine  the  distribution of the compound and its metabolites.85 Only a few 
pharmaceuticals aimed at the treatment of brain disorders have reached the market (3–5%) in the 
last decade due to the inability of most active compounds to cross the BBB.1 Direct injection into 
the striatum, circumventing the BBB entirely, has been used to deliver monoclonal antibodies 
bevacizumab and palivizumab to the brain to block angiogenesis of glioblastomas,86 but this 
method is not appropriate for all compounds. Many drug delivery strategies to the brain have 
focused on penetrating the BBB. 
Penetrating the BBB. Though the BBB is a tight membrane junction restricting the entry of 
most entities, several strategies have enabled the passage of drugs. Small molecules of >500 Da 
with high lipid solubility may penetrate the BBB by passive diffusion. Therefore, drugs can be 
incorporated into liposome-based particles for delivery to the brain.87 Other carriers, such as the 
cell-penetrating peptide TAT (Trans-Activator of Transcription) from HIV to treat Huntingtin’s 
disease, have been used.88 The permeability of the BBB has been increased by using sildenafil 
and vardenafil that inhibit phosphodiesterase 5 to improve the penetration of anti-tumor drugs 
into the brain.89 Alternatively, drug delivery can take advantage of influx changes in the BBB 
caused by CNS-related diseases, intracranial cell implantation or ex-vivo methods.90-92 Other 
strategies involve locally disrupting the BBB. One interesting and very promising method uses 
focused ultrasound to open the barrier.93  This method was used to treat glioblastomas in rats with 
induced tumors: A 400-KHz focused ultrasound was used to stimulate the BBB by delivering 
burst-tone ultrasound energy combined with microbubbles for increased penetration of 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) to glioblastomas.94 This strategy successfully enabled the 
drug to penetrate the brain and reach the tumor area. In another approach, a hyperosmotic 
solution was injected in the superficial temporal artery to open the BBB for a short time. The 
hyperosmotic solution forms temporary gaps and spaces, allowing the drug to diffuse into the 
brain and into the tumor.95 Finally, nanoparticles (NPs) and various polymers can be designed to 
have the right features to reach the region of interest in the brain. In the last decade, NPs are 
considered one of the most powerful ways to penetrate the BBB to reach the brain. 
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NANOPARTICLES AND DRUGS IN CELLS: EVALUATING UPTAKE AND 
TOXICITY BY MSI  
With their nanoscale size and customizable design, NPs have vast potential to carry and deliver 
active compounds to target sites. Many characteristics of NPs must be considered in drug 
delivery, including the effects of their size, shape and charge, the nanostructure itself and its 
interaction with cells and tissues, including uptake, intracellular distribution and toxicity. The 
physiochemical properties of NPs can be used to facilitate the controlled trigger and release of the 
drug cargo, with special consideration for controlled trafficking towards targeted cellular 
compartments such as the cytosol, nucleus and mitochondria. Until now, fluorescence imaging 
techniques, which require labeling the materials and various organelles, were used to visualize 
the co-localization of NPs with organelles in cells. Fluorescence microscopy is hampered by the 
inability to directly image the carrier and the cargo molecules simultaneously in the cell.87, 96-98  
MSI offers many advantages over fluorescence microscopy for the characterization of 
NPs. MSI can perform targeted analysis of NPs, its cargo, the metabolites and by-products. 
SIMS, in particular, provides superior lateral resolution (sub-micron resolution) for this type of 
analysis.   
A great advantage of TOF-SIMS–based techniques is the capability of performing depth 
profiling combined with MSI to produce 3D molecular images of cells and the analytes of 
interest. Applied to NPs, SIMS directly visualizes co-localized regions of NPs and drugs of 
interest at submicron lateral resolution and nanometer depth resolution. 3D SIMS analysis 
showed the distribution of the anti-arrhythmia compound amiodarone and its metabolites in 
NR8383 cells, an immortalized cell line derived from the lung (Figure 4a). With the 
simultaneous detection of the drug and its metabolites, isotopic labels are not needed. This was 
shown with the detection of desethylamiodarone metabolized by cytochrome P450.99 NPs have 
been previously localized in cells, demonstrated with TiO2
100 and polymer NPs, and due to their 
specific molecular signature, they could be easily identified without further processing. MSI of 
NPs can encounter problems with overlapping cell peaks.  Graham et al. increased the signal 
from the potential intrinsic cell peak using a background subtraction method to image micelle 
polymer NPs within endosomal compartments to overcome this problem.101 The method clearly 
demonstrated the isolation of NP related compound peaks.  
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An example where SIMS and optical microscopy can provide complementary information 
about the localization and uptake/release processes of NPs and associated drug in HeLa cells was 
shown by Proetto et al. In their work they combined illumination spectroscopy (SIM) and 
dynamic SIMS on the Cameca NanoSIMS to probe the polymeric NP Cy-15N-NP and its drug 
cargo 195Pt (Figure 4b.). The combination of the two techniques creates an imaging platform that 
can monitor the composition and integrity of the NP and its cargo from the cellular internalization 
to the drug release processes.98  
 
Quantification: how low can we go?  
Micro-scale quantification. In addition to the aforementioned qualitative characteristics 
of NPs and their cargo in cells, quantification of drug levels in tissue (micro-scale quantification) 
is critical for pharmacokinetics to understand the different mechanisms underlying a drug’s 
efficiency or toxicity. Before the development of MSI, autoradiography was the method of choice 
to quantify and visualize drug distributions in animals. However, autoradiography has some 
technical limitations as it is based on the detection of radioactivity. Moreover, many drug 
candidates cannot be assessed by autoradiography because it is not practical to synthetize a 
radiolabeled form of each candidate molecule.  
  
 To quantify NPs, additional parameters must be considered. First, the NPs, liposomes or 
micelles used can increase the local drug concentration gradients in the targeted areas of the 
brain. Because NPs must be fully biodegradable,102, 103 detecting NPs and their degradation 
products may be difficult if the biodegradation is very quick. Some other techniques have been 
used to determine the biodistribution and quantification of NPs. NPs have been visualized using 
systems able to image fluorescent and bioluminescent reporters. In fact, Liu et al. used the 
Caliper IVIS Spectrum Imaging System (PerkinElmer, MA, USA) to perform semi-quantitative 
studies on the brain, evaluating an epileptic drug delivery system loaded with a near-infrared 
dye.104 It is also possible to visualize and quantify NP’s using the more conventional in vivo MRI 
for drugs that preferentially accumulate in brain tumor tissues rather than healthy brain tissues.105, 
106 With the new techniques available that allow for high spatial (sub-micrometer) resolution, 
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such as SIMS,107 it is now possible to determine whether NPs are located close to the targeted 
cells or  incorporated the walls of these cells.  As another micro-scale quantification 
strategy, gold nanoparticles are easy to detect, less toxic to tissues, and amenable to synthesis and 
functionalization, thus are used for many biomedical applications108 including targeted drug 
delivery.109 Despite their wide application, gold nanoparticles still require much optimization. 
The relative quantification of gold nanoparticles can be accomplished using inductively-coupled 
mass spectrometry (ICP-MS), which can detect metals at low concentration. This analysis is 
performed by ionizing the sample with a plasma flame and analyzing the plasma to separate and 
quantify the ions.110 When coupled to a laser LA-ICP-MS can be used as an imaging technique to 
study the NP-based therapeutic delivery into the brain with achieving subcellular 1µm spatial 
resolution.111  
 PET is a nuclear medicine, functional imaging method used to observe metabolic 
processes in the body but can also detect NPs. PET detects pairs of gamma rays emitted by a 
tracer injected in the cells or in the NPs,  allowing quantification by tracking total radioactivity in 
the brain. For example, PET has been used to detect polymer NPs within the brain by using a 
radioligand to test different NP sizes and their biodistribution. Sirianni et al. developed a new 
technique for labeling NPs with an F-18-biotin derivative.112 PET has also been used to study 
BBB permeability with labeled gold nanoparticles in rodents to evaluate the most efficient drug 
delivery system.113 Different NPs can be studied using PET, such as boron. PET has been 
deployed to evaluate the best method to perform boron neutron capture therapy (BNCT),114 
which has been used to treat malignant brain tumors such as glioblastoma). This binary technique 
is based on the accumulation of boron-10 in tumor cells, which is then irradiated with low-energy 
neutrons to induce a fission reaction to produce irreparable DNA damage to cells containing 
boron-10; for this reason, accumulation of boron-10 must be selective for malignant tissue 
only.115  
As another nuclear-based imaging technique, single-photon emission computed 
tomography (SPECT) delivers a gamma-emitting radioisotope into the animal or the patient or by 
a radio-ligand attached to the NPs. This method allows biodistribution imaging of ultra-small 
NPs such as gadolinium-based NPs after their intravenous injection in rats.116 These particles 
absorb the photons and release photoelectrons and Auger electrons to damage the cells by the 
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creation of the reactive oxygen species. These NPs are used for radiation therapy to treat brain 
tumors. Gadolinium can also be used as a positive contrast agent in MRI.116, 117 Compared to PET 
and SPECT, MRI is easier to use for monitoring drug delivery to and in the brain. 
MSI can be applied to quantify levels of a compound and its metabolites in tissue.  
MALDI-based MSI has some limitations in performing quantitative analysis generally attributed 
to poor ion-signal reproducibility resulting from heterogeneous matrix crystallization, sample 
variation, tissue-specific ion suppression and laser energy fluctuation but most of them can be 
tackled with the appropriate use of an internal standard. Chumbley et al. applied an internal 
standard on top of liver tissue sections to quantify Rifampicin using MALDI and obtained 
comparable results to liquid-chromatography mass spectrometry.118 Furthermore, quantification 
requires a standard calibration curve; to perform quantification, the obtained concentration for 
each region of interest or for the full tissue section is plotted against the calibration curve to 
determine the drug amount in the tissue. MSI quantification is facilitated by dedicated software 
programs, such as msIQuant and Quantinetix,119, 120 which generates normalization against an 
internal standard upon selecting the ion of interest (Figure 5).   
Different MSI techniques have been used for micro-scale quantification of NPs. Laser 
desorption/ionization LDI, similar to MALDI but without using a matrix, can determine the 
biodistribution of NPs at attomole levels, making this method a potential tool for clinical analyses 
of biopsies and microbiopsies.121 MALDI has been used to quantify carbon-based NPs in the 
brain using the intrinsic carbon cluster fingerprint signal of the carbon NPs and a calibration 
curve established by tissue homogenates spiked with several concentrations of carbon.122  
 
Nano-scale quantification, the analysis of NPs at the cellular level, is important to evaluate a 
drug’s ability to penetrate cells. For example, effective BNCT depends on how much boron-10 
accumulates in tumor cells; therefore, quantification of boron-10 enables optimization of BNCT 
conditions. The first experiment using MSI to study the boron distribution in single cells was 
performed by Smith et al. in 1996 using an imaging mode of SIMS.123 They showed that the 
concentration of boron-10 was 3.5 times higher in the main tumor mass than in normal brain 
tissue, opening the door for nano-scale quantification. Five years later, the authors quantified the 
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ratio of boron in the brain to treat glioma and gliosarcoma by using a CAMECA IMS-3F ion 
microscope, pixel-to-pixel registration and ratio of the boron-10 and 12C images assuming 85% 
water content.123  A similar protocol has been used to perform subcellular quantification using 
SIMS on glioblastoma with a spatial resolution of 500 nm to test different treatment times. 
Furthermore, the subcellular distribution of boron-10 NPs within the nucleus and the cytoplasm 
was demonstrated.124 SIMS has also been used to demonstrate the heterogeneity of boron 
distribution depending of the cell cycle, which reveals the potential of MSI to investigate cellular 
events at different physiological points.125 Chandra et al. were also able to quantify the boron-10 
concentration in three subcellular compartments of the nucleus, the nucleus itself, the 
mitochondria-rich perinuclear cytoplasm and the cytoplasm to compare the penetration efficiency 
of boron. They showed that boron-10 was distributed evenly throughout the cell with the 
exception of the perinuclear cytoplasmic region.126 MSI allows also the study and the 
optimization of boron delivery agents and injection sites to evaluate the best candidates and 
methods based on the biodistribution of the particles in the brain, tumor tissues and the blood.127  
Nano-scale quantification can also be performed using proton-induced X-ray emission 
spectroscopy (micro-PIXE), a technique used to measure the absorbed microparticles on the 
lorica of marine zooplankton species.128 Tomíc et al. used micro-PIXE to study the absorption of 
gold particles by human dendritic cells and demonstrated that smaller gold nanoparticles 
effectively accumulated and had stronger inhibitory effects on the maturation and antitumor 
functions of dendritic cells inducing necrosis of tumor cells. They concluded that smaller gold 
particles have the best potential to be used in photothermal therapy and cancer diagnostics due to 
their ability to penetrate cells.129, 130  
CONCLUSIONS 
The current review describes the vast potential of MSI in nanomedicine. It has proven itself as an 
rapidly maturing technique the study of the distribution of drugs, metabolites and nanoparticles in 
cells and tissues. It is very important to choose an MSI technique suited to the molecules or 
elements at the heart of the research question posed. We have discussed the challenges posed by 
the BBB in developing important therapeutics to combat many diseases, and the possibility of 
using MSI to assist in understanding the penetration mechanisms of drugs and NPs through the 
BBB.  We have demonstrated that the new developments in MSI during the last decades allow us 
15 
 
to study the composition, distribution and quantification of drugs and their metabolites in tissue, 
as well as the uptake, intracellular distribution and toxicity of NPs in cells.. The three techniques 
reviewed here—MALDI, SIMS and DESI—are complementary and allow a better understanding 
of the functionalities of these particles as the drug carrier as well as the cargo itself. MSI allows 
the detection of both the drugs, their nanoparticle carriers and their (bio-) degradation products. 
In summary, MSI has proven its role to unravel mechanisms during the optimization of 
nanoparticle therapeutic designs, while monitoring pathogenesis of different neurodegenerative 
diseases and therefore, opening doors to great breakthroughs in neurosciences.  
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Figure 1. Mass Spectrometry Imaging workflow. 1: Production of the charged ions by the ion source from the biological tissue 
section mounted on a slide. The ions are charged, positively or negatively, which allow them to penetrate into the analyzer. 2: The 
ions penetrate the analyzer and are separated by their mass-to-charge ratio under vacuum condition by an electric/magnetic field. 
3: The ions reach the detector; the lighter ions reach the detector first followed by the heavier ones. 4: Mass spectra are obtained 
with the different molecules corresponding to the peaks present in the spectra. Each molecule can be selected to visualize its 
distribution in the tissue.   
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Figure 2. Overview of DESI, SIMS and MALDI MSI workflow. The organ is harvested from the animal or patient and snap-
frozen or embedded in gelatin. Fresh frozen or embedded tissue is cut and mounted on a slide to perform SIMS or DESI. For 
MALDI, the tissue section has to be mounted on a conductive slide and a matrix has to be sprayed on top the tissue. In SIMS, an 
ion beam bombards the surface of the tissue, generating secondary ions for detection. In DESI, a charged solvent extracts the ions 
from the tissue for detection.  In MALDI, a laser beam with the help of the matrix generates ions for detection.  
 
 
19 
 
 
 
Figure 3. Comparison of heme and fluorescein images from MALDI-TOF MSI at 50-mm (A) and 25-mm (B) resolution with 
fluorescence image in the same mouse brain section (10-mm thickness) with pre-injected fluorescein. i: fluorescence image of 
blood vessels from fluorescein (excitation at 490 nm, emission at 520 nm); ii: heme image (red, m/z 616.2 ± 0.1 (top) and 616.1 ± 
0.1 (bottom)) from MALDI MSI; iii: fluorescein image (blue, m/z 333.3 ± 0.1 (top) and m/z 333.0 ± 0.1 (bottom)) from MALDI 
MSI; iv: overlay of heme (red) and fluorescein (blue) from MALDI MSI. In i–iv, yellow arrows indicate the lateral ventricle 
delineated by fluorescein with the absence of heme.  v: H&E staining of a sister section from (A) with the expanded view showing 
the lateral ventricle; The red arrows indicate the region of blood.  
 
 
Figure 4. Imaging nanoparticles. A. 3D rendering of macrophages dosed with amiodarone. The internal distribution of 
amiodarone (m/z 640.0, green) is visible after the surface of the cells was sputtered away (1.85 × 1014 Ar2000/cm2, slices 5–40). 
The blue and red pixels represent the distribution of the lipid markers at m/z 184.1 and the nuclear-markers at m/z 81.0, 
respectively. Adapted with permission from Passarelli et al. Single-Cell Analysis: Visualizing Pharmaceutical and Metabolite 
Uptake in Cells with Label-Free 3D Mass spectrometry Imaging. Anal Chem. 2015 Jul 7;87(13):6696-702. doi: 
10.1021/acs.analchem.5b00842. Epub 2015 Jun 23. Copyright 2015 American Chemical Society. B: Composite NanoSIMS image 
of a HeLa cell incubated with 15 µM Cy-15N-NP where 195Pt (red) and 15N enrichment (green) and overlaid on the secondary ion 
image. Yellow regions indicate colocalization of signals. The scale bar represents 10 µm. Adapted with permission from Proetto 
et al. Cellular Delivery of nanoparticles revealed with Combined Optical and Isotopic Nanoscopy. ACS Nano, 2016, 10 (4), pp 
4046–4054. Copyright 2016 American Chemical Society.  
20 
 
 
Figure 5. Quantification protocol using msIQuant. The workflow for utilizing the software is exemplified by the analysis of a 
brain tissue section from an animal that had been treated with a drug. (A) Ion image of the drug from a sagittal mouse brain tissue 
section and (B) ion image of an isotope-labeled internal standard that was applied to the tissue section before matrix application. 
(C) The drug’s ion intensity is then normalized in each pixel using the data for the internal standard. (D) A calibration standard 
curve is created by applying known quantities of the drug to separate regions of a control mouse brain tissue section and then 
selecting and annotating the corresponding regions of interest (ROIs). The internal standard is also applied to the tissue section 
before matrix application and the ion intensity is normalized in each pixel using the internal standard. (E) A calibration standard 
curve is automatically created using the data for the normalized calibration standards. (F) Three different brain regions, cortex 
(CTX), hippocampus (HIP), and caudate-putamen (CPu), are selected as ROIs, and the drug concentrations (pmol/mg) and 
amounts (pmol) in each are calculated using the evaluation function of msIQuant. Reprinted with permission from Kallback et al. 
msIquant – Quantitation Software for Mass Spectrometry Imaging enabling Fast Access, Visualization, and Analysis of Large 
Data Set. Anal Chem. 2016 Apr 19;88(8):4346-53. doi: 10.1021/acs.analchem.5b04603. Epub 2016 Apr 5. Copyright 2016 
American Chemical Society.  
 
 
 
 
1 W. M. Pardridge, Pharm Res 2007, 24, 1733-44 10.1007/s11095-007-9324-2. 
2 M. Karas, F. Hillenkamp, Anal Chem 1988, 60, 2299-301. 
3 F. Hillenkamp, M. Karas, R. C. Beavis, B. T. Chait, Anal Chem 1991, 63, 1193A-1203A. 
4 J. B. Fenn, M. Mann, C. K. Meng, S. F. Wong, C. M. Whitehouse, Science 1989, 246, 64-71. 
5 E. Schoenbauer, P. Szomolanyi, T. Shiomi, V. Juras, S. Zbyn, L. Zak, M. Weber, S. Trattnig, Journal 
of Biomechanics 2015, 48, 3349-3355 10.1016/j.jbiomech.2015.06.016. 
6 Y. Hirata, Y. Inaba, N. Kobayashi, H. Ike, Y. Yukizawa, H. Fujimaki, T. Tezuka, U. Tateishi, T. Inoue, 
T. Saito, Journal of Orthopaedic Research 2015, 33, 78-83 10.1002/jor.22717. 
7 D. Isik, C. Isik, N. Apaydin, Y. Ustu, M. Ugurlu, M. Bozkurt, Clinical Anatomy 2015, 28, 672-677 
10.1002/ca.22550. 
21 
 
8 Z. Fan, L. M. Sun, Y. J. Huang, Y. Z. Wang, M. J. Zhang, Nature Nanotechnology 2016, 11, 388-+ 
10.1038/Nnano.2015.312. 
9 M. J. Sun, B. Sun, Y. Liu, Q. D. Shen, S. J. Jiang, Scientific Reports 2016, 6,  Artn 22368 
10.1038/Srep22368. 
10 J. Hanrieder, P. Malmberg, A. G. Ewing, Biochimica Et Biophysica Acta-Proteins and Proteomics 
2015, 1854, 718-731 10.1016/j.bbapap.2014.12.026. 
11 M. Lalowski, F. Magni, V. Mainini, E. Monogioudi, A. Gotsopoulos, R. Soliymani, C. Chinello, M. 
Baumann, Nephrology Dialysis Transplantation 2013, 28, 1648-1656 10.1093/ndt/gft008. 
12 H. E. Bowrey, D. M. Anderson, P. Pallitto, D. B. Gutierrez, J. Fan, R. K. Crouch, K. L. Schey, Z. 
Ablonczy, Proteomics Clinical Applications 2016, 10, 391-402 10.1002/prca.201500103. 
13 A. Nilsson, R. J. A. Goodwin, M. Shariatgorji, T. Vallianatou, P. J. H. Webborn, P. E. Andren, 
Analytical Chemistry 2015, 87, 1437-1455 10.1021/ac504734s. 
14 J. Pol, M. Strohalm, V. Havlicek, M. Volny, Histochemistry and Cell Biology 2010, 134, 423-443 
10.1007/s00418-010-0753-3. 
15 P. Neubert, A. Walch, Expert Review of Proteomics 2013, 10, 259-273 10.1586/Epr.13.19. 
16 M. Aichler, A. Walch, Laboratory Investigation 2015, 95, 422-431 10.1038/labinvest.2014.156. 
17 C. Schone, H. Hofler, A. Walch, Clinical Biochemistry 2013, 46, 539-545 
10.1016/j.clinbiochem.2013.01.018. 
18 E. R. A. van Hove, T. R. Blackwell, I. Klinkert, G. B. Eijkel, R. M. A. Heeren, K. Glunde, Cancer 
Research 2010, 70, 9012-9021 10.1158/0008-5472.CAN-10-0360. 
19 B. Cillero-Pastor, G. B. Eijkel, A. Kiss, F. J. Blanco, R. M. Heeren, Arthritis Rheum 2013, 65, 710-20 
10.1002/art.37799. 
20 M. Shariatgorji, P. Svenningsson, P. E. Andren, Neuropsychopharmacology 2014, 39, 34-49 
10.1038/npp.2013.215. 
21 K. Chughtai, R. M. A. Heeren, Chemical Reviews 2010, 110, 3237-3277 10.1021/cr100012c. 
22 J. L. Norris, R. M. Caprioli, Chemical Reviews 2013, 113, 2309-2342 10.1021/cr3004295. 
23 P. Chaurand, J Proteomics 2012, 75, 4883-92 10.1016/j.jprot.2012.04.005. 
24 R. D. Macfarlane, D. F. Torgerson, Science 1976, 191, 920-5. 
25 B. Sundqvist, P. Roepstorff, J. Fohlman, A. Hedin, P. Hakansson, I. Kamensky, M. Lindberg, M. 
Salehpour, G. Sawe, Science 1984, 226, 696-8. 
26 G. Bolbach, A. Viari, R. Galera, A. Brunot, J. C. Blais, International Journal of Mass Spectrometry 
and Ion Processes 1992, 112, 93-100 Doi 10.1016/0168-1176(92)87034-C. 
27 L. Van Vaeck, A. Adriaens, R. Gijbels, Mass Spectrometry Reviews 1999, 18, 1-47. 
28 J. S. Fletcher, S. Rabbani, A. Henderson, P. Blenkinsopp, S. P. Thompson, N. P. Lockyer, J. C. 
Vickerman, Analytical Chemistry 2008, 80, 9058-9064 10.1021/ac8015278. 
29 M. K. Passarelli, A. G. Ewing, N. Winograd, Analytical Chemistry 2013, 85, 2231-2238 
10.1021/ac303038j. 
30 A. M. Piwowar, S. Keskin, M. O. Delgado, K. Shen, J. J. Hue, I. Lanekoff, A. G. Ewing, N. Winograd, 
Surface and Interface Analysis 2013, 45, 302-304 10.1002/sia.4882. 
31 T. B. Angerer, M. D. Pour, P. Malmberg, J. S. Fletcher, Analytical Chemistry 2015, 87, 4305-4313 
10.1021/ac504774y. 
32 H. Nygren, P. Malmberg, Proteomics 2010, 10, 1694-1698 10.1002/pmic.200900782. 
33 K. L. Busch, B. H. Hsu, Y. X. Xie, R. G. Cooks, Analytical Chemistry 1983, 55, 1157-1160 
10.1021/ac00258a040. 
34 A. F. M. Altelaar, J. van Minnen, C. R. Jimenez, R. M. A. Heeren, S. R. Piersma, Analytical 
Chemistry 2005, 77, 735-741 10.1021/ac048329g. 
22 
 
35 L. Adriaensen, F. Vangaever, R. Gijbels, Analytical Chemistry 2004, 76, 6777-6785 
10.1021/ac049108d. 
36 A. Delcorte, N. Medard, P. Bertrand, Analytical Chemistry 2002, 74, 4955-4968 
10.1021/ac020125h. 
37 A. F. M. Altelaar, I. Klinkert, K. Jalink, R. P. J. de Lange, R. A. H. Adan, R. M. A. Heeren, S. R. 
Piersma, Analytical Chemistry 2006, 78, 734-742 10.1021/ac0513111. 
38 E. R. Fuoco, G. Gillen, M. B. J. Wijesundara, W. E. Wallace, L. Hanley, Journal of Physical 
Chemistry B 2001, 105, 3950-3956 10.1021/jp0033317. 
39 D. E. Weibel, N. Lockyer, J. C. Vickerman, Applied Surface Science 2004, 231, 146-152 
10.1016/j.apsusc.2004.03.098. 
40 S. C. C. Wong, R. Hill, P. Blenkinsopp, N. P. Lockyer, D. E. Weibel, J. C. Vickerman, Applied Surface 
Science 2003, 203, 219-222 Pii S0169-4332(02)00629-3 
Doi 10.1016/S0169-4332(02)00629-3. 
41 S. Sheraz, A. Barber, J. S. Fletcher, N. P. Lockyer, J. C. Vickerman, Analytical Chemistry 2013, 85, 
5654-5658 10.1021/ac4013732. 
42 Y. Nakata, Y. Honda, S. Ninomiya, T. Seki, T. Aoki, J. Matsuo, Applied Surface Science 2008, 255, 
1591-1594 10.1016/j.apsusc.2008.05.108. 
43 B. N. Jones, J. Matsuo, Y. Nakata, H. Yamada, J. Watts, S. Hinder, V. Palitsin, R. Webb, Surface and 
Interface Analysis 2011, 43, 249-252 10.1002/sia.3520. 
44 M. J. Bailey, B. N. Jones, S. Hinder, J. Watts, S. Bleay, R. P. Webb, Nuclear Instruments & Methods 
in Physics Research Section B-Beam Interactions with Materials and Atoms 2010, 268, 1929-1932 
10.1016/j.nimb.2010.02.104. 
45 B. Jencic, L. Jeromel, N. O. Potocnik, K. Vogel-Mikus, E. Kovacec, M. Regvar, Z. Siketic, P. Vavpetic, 
Z. Rupnik, K. Bucar, M. Kelemen, J. Kovac, P. Pelicon, Nuclear Instruments & Methods in Physics Research 
Section B-Beam Interactions with Materials and Atoms 2016, 371, 205-210 10.1016/j.nimb.2015.10.047. 
46 G. L. Fisher, A. L. Bruinen, N. O. Potocnik, J. S. Hammond, S. R. Bryan, P. E. Larson, R. M. A. 
Heeren, Analytical Chemistry 2016, 88, 6433-6440 10.1021/acs.analchem.6b01022. 
47 L. A. McDonnell, R. M. A. Heeren, Mass Spectrometry Reviews 2007, 26, 606-643 
10.1002/mas.20124. 
48 P. J. Todd, T. G. Schaaff, P. Chaurand, R. M. Caprioli, Journal of Mass Spectrometry 2001, 36, 355-
369 Doi 10.1002/Jms.153. 
49 A. Zavalin, E. M. Todd, P. D. Rawhouser, J. H. Yang, J. L. Norris, R. M. Caprioli, Journal of Mass 
Spectrometry 2012, 47, 1473-1481 10.1002/jms.3108. 
50 N. O. Potocnik, T. Porta, M. Becker, R. M. A. Heeren, S. R. Ellis, Rapid Communications in Mass 
Spectrometry 2015, 29, 2195-2203 10.1002/rcm.7379. 
51 A. F. M. Altelaar, I. M. Taban, L. A. McDonnell, P. D. E. M. Verhaert, R. P. J. de Lange, R. A. H. 
Adan, W. J. Mooi, R. M. A. Heeren, S. R. Piersma, International Journal of Mass Spectrometry 2007, 260, 
203-211 10.1016/j.ijms.2006.09.028. 
52 S. Guenther, A. Rompp, W. Kummer, B. Spengler, International Journal of Mass Spectrometry 
2011, 305, 228-237 10.1016/j.ijms.2010.11.011. 
53 D. Calligaris, D. R. Feldman, I. Norton, O. Olubiyi, A. N. Changelian, R. Machaidze, M. L. Vestal, E. 
R. Laws, I. F. Dunn, S. Santagata, N. Y. R. Agar, Proceedings of the National Academy of Sciences of the 
United States of America 2015, 112, 9978-9983 10.1073/pnas.1423101112. 
54 J. Hanrieder, G. Wicher, J. Bergquist, M. Andersson, A. Fex-Svenningsen, Analytical and 
Bioanalytical Chemistry 2011, 401, 135-147 10.1007/s00216-011-5043-y. 
55 B. Chatterji, C. Dickhut, S. Mielke, J. Kruger, I. Just, S. Glage, M. Meier, D. Wedekind, A. Pich, 
Proteomics 2014, 14, 1674-1687 10.1002/pmic.201300558. 
23 
 
56 J. Hanrieder, A. Ljungdahl, M. Andersson, Jove-Journal of Visualized Experiments 2012,  Artn 
E3445 
10.3791/3445. 
57 Z. Takats, J. M. Wiseman, B. Gologan, R. G. Cooks, Science 2004, 306, 471-473 DOI 
10.1126/science.1104404. 
58 D. R. Ifa, J. M. Wiseman, Q. Y. Song, R. G. Cooks, International Journal of Mass Spectrometry 
2007, 259, 8-15 10.1016/j.ijms.2006.08.003. 
59 V. Kertesz, G. J. Van Berkel, Rapid Communications in Mass Spectrometry 2008, 22, 3846-3850 
10.1002/rcm.3812. 
60 S. Myung, J. M. Wiseman, S. J. Valentine, Z. Takats, R. G. Cooks, D. E. Clemmer, Journal of 
Physical Chemistry B 2006, 110, 5045-5051 10.1021/jp052663e. 
61 Y. S. Song, N. Talaty, W. A. Tao, Z. Z. Pan, R. G. Cooks, Chemical Communications 2007, 61-63 
10.1039/b615724f. 
62 Z. Takats, I. Cotte-Rodriguez, N. Talaty, H. W. Chen, R. G. Cooks, Chemical Communications 2005, 
1950-1952 10.1039/b418697d. 
63 I. Cotte-Rodriguez, Z. Takats, N. Talaty, H. W. Chen, R. G. Cooks, Analytical Chemistry 2005, 77, 
6755-6764 10.1021/ac050995. 
64 K. Skraskova, A. Khmelinskii, W. M. Abdelmoula, S. De Munter, M. Baes, L. McDonnell, J. Dijkstra, 
R. M. A. Heeren, Journal of the American Society for Mass Spectrometry 2015, 26, 948-957 
10.1007/s13361-015-1146-6. 
65 A. L. Dill, D. R. Ifa, N. E. Manicke, A. B. Costa, J. A. Ramos-Vara, D. W. Knapp, R. G. Cooks, 
Analytical Chemistry 2009, 81, 8758-8764 10.1021/ac901028b. 
66 E. Esquenazi, P. C. Dorrestein, W. H. Gerwick, Proceedings of the National Academy of Sciences of 
the United States of America 2009, 106, 7269-7270 10.1073/pnas.0902840106. 
67 A. L. Lane, L. Nyadong, A. S. Galhena, T. L. Shearer, E. P. Stout, R. M. Parry, M. Kwasnik, M. D. 
Wang, M. E. Hay, F. M. Fernandez, J. Kubanek, Proceedings of the National Academy of Sciences of the 
United States of America 2009, 106, 7314-7319 10.1073/pnas.0812020106. 
68 J. M. Wiseman, D. R. Ifa, Y. X. Zhu, C. B. Kissinger, N. E. Manicke, P. T. Kissinger, R. G. Cooks, 
Proceedings of the National Academy of Sciences of the United States of America 2008, 105, 18120-
18125 10.1073/pnas.0801066105. 
69 R. G. Cooks, Z. Ouyang, Z. Takats, J. M. Wiseman, Science 2006, 311, 1566-1570 
10.1126/science.1119426. 
70 C. P. Wu, D. R. Ifa, N. E. Manicke, R. G. Cooks, Analytical Chemistry 2009, 81, 7618-7624 
10.1021/ac901003u. 
71 D. Lostun, C. J. Perez, P. Licence, D. A. Barrett, D. R. Ifa, Analytical Chemistry 2015, 87, 3286-3293 
10.1021/ac5042445. 
72 M. Girod, Y. Z. Shi, J. X. Cheng, R. G. Cooks, Analytical Chemistry 2011, 83, 207-215 
10.1021/ac102264z. 
73 J. C. Vickerman, Analyst 2011, 136, 2199-2217 10.1039/c1an00008j. 
74 K. Tabanor, P. Lee, P. Kiptoo, I. Y. Choi, E. B. Sherry, C. S. Eagle, T. D. Williams, T. J. Siahaan, 
Molecular Pharmaceutics 2016, 13, 379-390 10.1021/acs.molpharmaceut.5b00607. 
75 A. Srimany, C. George, H. R. Naik, D. G. Pinto, N. Chandrakumar, T. Pradeep, Phytochemistry 
2016, 125, 35-42 10.1016/j.phytochem.2016.02.002. 
76 A. S. Attia, K. A. Schroeder, E. H. Seeley, K. J. Wilson, N. D. Hammer, D. C. Colvin, M. L. Manier, J. 
J. Nicklay, K. L. Rose, J. C. Gore, R. M. Caprioli, E. P. Skaar, Cell Host & Microbe 2012, 11, 664-673 
10.1016/j.chom.2012.04.018. 
24 
 
77 J. Oetjen, M. Aichler, D. Trede, J. Strehlow, J. Berger, S. Heldmann, M. Becker, M. Gottschalk, J. 
H. Kobarg, S. Wirtz, S. Schiffler, H. Thiele, A. Walch, P. Maass, T. Alexandrov, Journal of Proteomics 2013, 
90, 52-60 10.1016/j.jprot.2013.03.013. 
78 L. Jiang, T. R. Greenwood, D. Artemov, V. Raman, P. T. Winnard, R. M. A. Heeren, Z. M. Bhujwalla, 
K. Glunde, Neoplasia 2012, 14, 732-741 10.1593/neo.12858. 
79 N. Braidy, A. Poljak, C. Marjo, H. Rutlidge, A. Rich, T. Jayasena, N. C. Inestrosa, P. Sachdev, 
Frontiers in Aging Neuroscience 2014, 6,  Artn 138 
10.3389/Fnagi.2014.00138. 
80 L. Carlred, W. Michno, I. Kaya, P. Sjovall, S. Syvanen, J. Hanrieder, Journal of Neurochemistry 
2016, 138, 469-478 10.1111/jnc.13645. 
81 J. H. Hong, J. W. Kang, D. K. Kim, S. H. Baik, K. H. Kim, S. R. Shanta, J. H. Jung, I. Mook-Jung, K. P. 
Kim, Journal of Lipid Research 2016, 57, 36-45 10.1194/jlr.M057869. 
82 J. L. He, Z. G. Luo, L. Huang, J. M. He, Y. Chen, X. F. Rong, S. B. Jia, F. Tang, X. H. Wang, R. P. 
Zhang, J. J. Zhang, J. G. Shi, Z. Abliz, Analytical Chemistry 2015, 87, 5372-5379 
10.1021/acs.analchem.5b00680. 
83 A. L. Bruinen, C. van Oevelen, G. B. Eijkel, M. Van Heerden, F. Cuyckens, R. M. A. Heeren, Journal 
of the American Society for Mass Spectrometry 2016, 27, 117-123 10.1007/s13361-015-1254-3. 
84 X. H. Liu, J. L. Ide, I. Norton, M. A. Marchionni, M. C. Ebling, L. Y. Wang, E. Davis, C. M. Sauvageot, 
S. Kesari, K. A. Kellersberger, M. L. Easterling, S. Santagata, D. D. Stuart, J. Alberta, J. N. Agar, C. D. Stiles, 
N. Y. R. Agar, Scientific Reports 2013, 3,  Artn 2859 
10.1038/Srep02859. 
85 S. Okutan, H. S. Hansen, C. Janfelt, Proteomics 2016, 16, 1634-1641 10.1002/pmic.201500422. 
86 R. Ait-Belkacem, C. Berenguer, C. Villard, L. Ouafik, D. Figarella-Branger, A. Beck, O. Chinot, D. 
Lafitte, MAbs 2014, 6, 1385-93 10.4161/mabs.34405. 
87 M. Masserini, ISRN Biochem 2013, 2013, 238428 10.1155/2013/238428. 
88 Y. Arribat, Y. Talmat-Amar, A. Paucard, P. Lesport, N. Bonneaud, C. Bauer, N. Bec, M. L. 
Parmentier, L. Benigno, C. Larroque, P. Maurel, F. Maschat, Acta Neuropathologica Communications 
2014, 2,  ARTN 86 
10.1186/s40478-014-0086-x. 
89 H. Hu, L. Jiang, H. Pu, Y. Chen, X. J. Liu, Physical Review Letters 2013, 110,  Artn 020401 
10.1103/Physrevlett.110.020401. 
90 B. Obermeier, R. Daneman, R. M. Ransohoff, Nature Medicine 2013, 19, 1584-1596 
10.1038/nm.3407. 
91 B. V. Zlokovic, Neuron 2008, 57, 178-201 10.1016/j.neuron.2008.01.003. 
92 H. J. van de Haar, S. Burgmans, J. F. A. Jansen, M. J. P. van Osch, M. A. van Buchem, M. Muller, P. 
A. M. Hofman, F. R. J. Verhey, W. H. Backes, Radiology 2016, 281, 527-535 10.1148/radiol.2016152244. 
93 K. F. Timbie, B. P. Mead, R. J. Price, Journal of Controlled Release 2015, 219, 61-75 
10.1016/j.jconrel.2015.08.059. 
94 H. L. Liu, M. Y. Hua, P. Y. Chen, P. C. Chu, C. H. Pan, H. W. Yang, C. Y. Huang, J. J. Wang, T. C. Yen, 
K. C. Wei, Radiology 2010, 255, 415-425 10.1148/radiol.10090699. 
95 S. Sato, T. Kawase, S. Harada, H. Takayama, S. Suga, Acta Neurochirurgica 1998, 140, 1135-+ DOI 
10.1007/s007010050227. 
96 Y. Cheng, R. A. Morshed, B. Auffinger, A. L. Tobias, M. S. Lesniak, Advanced Drug Delivery 
Reviews 2014, 66, 42-57 10.1016/j.addr.2013.09.006. 
25 
 
97 I. P. Kaur, R. Bhandari, S. Bhandari, V. Kakkar, Journal of Controlled Release 2008, 127, 97-109 
10.1016/j.jconrel.2007.12.018. 
98 M. T. Proetto, C. R. Anderton, D. H. Hu, C. J. Szymanski, Z. H. Zhu, J. P. Patterson, J. K. Kammeyer, 
L. G. Nilewski, A. M. Rush, N. C. Bell, J. E. Evans, G. Orr, S. B. Howell, N. C. Gianneschi, Acs Nano 2016, 10, 
4046-4054 10.1021/acsnano.5b06477. 
99 M. K. Passarelli, C. F. Newman, P. S. Marshall, A. West, I. S. Gilmore, J. Bunch, M. R. Alexander, C. 
T. Dollery, Analytical Chemistry 2015, 87, 6696-6702 10.1021/acs.analchem.5b00842. 
100 J. N. Audinot, A. Georgantzopoulou, J. P. Piret, A. C. Gutleb, D. Dowsett, H. N. Migeon, L. 
Hoffmann, Surface and Interface Analysis 2013, 45, 230-233 10.1002/sia.5099. 
101 D. J. Graham, J. T. Wilson, J. J. Lai, P. S. Stayton, D. G. Castner, Biointerphases 2016, 11,  Artn 
02a304 
10.1116/1.4934795. 
102 A. Mahapatro, D. K. Singh, Journal of Nanobiotechnology 2011, 9,  Artn 55 
10.1186/1477-3155-9-55. 
103 T. J. Spitzenberger, D. Heilman, C. Diekmann, E. V. Batrakova, A. V. Kabanov, H. E. Gendelman, 
W. F. Elmquist, Y. Persidsky, Journal of Cerebral Blood Flow and Metabolism 2007, 27, 1033-1042 
10.1038/sj.jcbfm.9600414. 
104 J. S. Liu, Y. J. He, J. Zhang, J. J. Li, X. R. Yu, Z. L. Cao, F. M. Meng, Y. W. Zhao, X. Y. Wu, T. Shen, Z. 
Hong, Biomaterials 2016, 74, 64-76 10.1016/j.biomaterials.2015.09.041. 
105 X. R. Yu, J. H. Wang, J. S. Liu, S. Shen, Z. L. Cao, J. W. Pan, S. Y. Zhou, Z. Q. Pang, D. Y. Geng, J. 
Zhang, Biomaterials 2016, 76, 173-186 10.1016/j.biomaterials.2015.10.050. 
106 M. I. Koukourakis, S. Koukouraki, I. Fezoulidis, N. Kelekis, G. Kyrias, S. Archimandritis, N. 
Karkavitsas, British Journal of Cancer 2000, 83, 1281-1286 DOI 10.1054/bjoc.2000.1459. 
107 M. Korsgen, A. Pelster, K. Dreisewerd, H. F. Arlinghaus, Journal of the American Society for Mass 
Spectrometry 2016, 27, 277-284 10.1007/s13361-015-1275-y. 
108 P. M. Tiwari, K. Vig, V. A. Dennis, S. R. Singh, Nanomaterials 2011, 1, 31-63 
10.3390/nano1010031. 
109 H. Daraee, A. Eatemadi, E. Abbasi, S. F. Aval, M. Kouhi, A. Akbarzadeh, Artificial Cells 
Nanomedicine and Biotechnology 2016, 44, 410-422 10.3109/21691401.2014.955107. 
110 F. Laborda, E. Bolea, J. Jimenez-Lamana, Analytical Chemistry 2014, 86, 2270-2278 
10.1021/ac402980q. 
111 H. A. O. Wang, D. Grolimund, C. Giesen, C. N. Borca, J. R. H. Shaw-Stewart, B. Bodenmiller, D. 
Gunther, Analytical Chemistry 2013, 85, 10107-10116 10.1021/ac400996x. 
112 R. W. Sirianni, M. Q. Zheng, T. R. Patel, T. Shafbauer, J. Zhou, W. M. Saltzman, R. E. Carson, Y. 
Huang, Bioconjug Chem 2014, 25, 2157-65 10.1021/bc500315j. 
113 J. Frigell, I. Garcia, V. Gomez-Vallejo, J. Llop, S. Penades, Journal of the American Chemical Society 
2014, 136, 449-457 10.1021/ja411096m. 
114 Y. Iguchi, H. Michiue, M. Kitamatsu, Y. Hayashi, F. Takenaka, T. Nishiki, H. Matsui, Biomaterials 
2015, 56, 10-17 10.1016/j.biomaterials.2015.03.061. 
115 T. Yamamoto, K. Nakai, A. Matsumura, Cancer Letters 2008, 262, 143-152 
10.1016/j.canlet.2008.01.021. 
116 I. Miladi, G. Le Duc, D. Kryza, A. Berniard, P. Mowat, S. Roux, J. Taleb, P. Bonazza, P. Perriat, F. 
Lux, O. Tillement, C. Billotey, M. Janier, Journal of Biomaterials Applications 2013, 28, 385-394 
10.1177/0885328212454315. 
26 
 
117 G. Strohbehn, D. Coman, L. Han, R. R. T. Ragheb, T. M. Fahmy, A. J. Huttner, F. Hyder, J. M. 
Piepmeier, W. M. Saltzman, J. B. Zhou, Journal of Neuro-Oncology 2015, 121, 441-449 10.1007/s11060-
014-1658-0. 
118 C. W. Chumbley, M. L. Reyzer, J. L. Allen, G. A. Marriner, L. E. Via, C. E. Barry, R. M. Caprioli, 
Analytical Chemistry 2016, 88, 2392-2398 10.1021/acs.analchem.5b04409. 
119 P. Kallback, A. Nilsson, M. Shariatgorji, P. E. Andren, Analytical Chemistry 2016, 88, 4346-4353 
10.1021/acs.analchem.5b04603. 
120 Z. C. Zhang, J. Kuang, L. J. Li, Analyst 2013, 138, 6600-6606 10.1039/c3an01225e. 
121 B. Yan, S. T. Kim, C. S. Kim, K. Saha, D. F. Moyano, Y. Q. Xing, Y. Jiang, A. L. Roberts, F. S. Alfonso, 
V. M. Rotello, R. W. Vachet, Journal of the American Chemical Society 2013, 135, 12564-12567 
10.1021/ja406553f. 
122 S. M. Chen, C. Q. Xiong, H. H. Liu, Q. Q. Wan, J. Hou, Q. He, A. Badu-Tawiah, Z. X. Nie, Nature 
Nanotechnology 2015, 10, 176-182 10.1038/Nnano.2014.282. 
123 D. R. Smith, S. Chandra, J. A. Coderre, G. H. Morrison, Cancer Research 1996, 56, 4302-4306. 
124 S. Chandra, D. R. Lorey, D. R. Smith, Radiation Research 2002, 157, 700-710 Doi 10.1667/0033-
7587(2002)157[0700:Qssims]2.0.Co;2. 
125 S. Chandra, W. Tjarks, D. R. Lorey, R. F. Barth, Journal of Microscopy-Oxford 2008, 229, 92-103 
DOI 10.1111/j.1365-2818.2007.01869.x. 
126 S. Chandra, R. F. Barth, S. A. Haider, W. L. Yang, T. Y. Huo, A. L. Shaikh, G. W. Kabalka, Plos One 
2013, 8,  ARTN e75377 
10.1371/journal.pone.0075377. 
127 R. F. Barth, G. W. Kabalka, W. L. Yang, T. Y. Huo, R. J. Nakkula, A. L. Shaikh, S. A. Haider, S. 
Chandra, Applied Radiation and Isotopes 2014, 88, 38-42 10.1016/j.apradiso.2013.11.133. 
128 N. Ogrinc, P. Pelicon, P. Vavpetic, M. Kelemen, N. Grlj, L. Jeromel, S. Tomic, M. Colic, A. Beran, 
Nuclear Instruments & Methods in Physics Research Section B-Beam Interactions with Materials and 
Atoms 2013, 306, 121-124 10.1016/j.nimb.2012.12.060. 
129 S. Tomic, J. Dokic, S. Vasilijic, N. Ogrinc, R. Rudolf, P. Pelicon, D. Vucevic, P. Milosavljevic, S. 
Jankovic, I. Anzel, J. Rajkovic, M. S. Rupnik, B. Friedrich, M. Colic, Plos One 2014, 9,  ARTN e96584 
10.1371/journal.pone.0096584. 
130 Y. P. Kim, H. K. Shon, S. K. Shin, T. G. Lee, Mass Spectrometry Reviews 2015, 34, 237-247 
10.1002/mas.21437. 
 
 
